2024
A Validated Algorithm to Identify Hepatic Decompensation in the Veterans Health Administration Electronic Health Record System
Haque L, Tate J, Chew M, Caniglia E, Taddei T, Re V. A Validated Algorithm to Identify Hepatic Decompensation in the Veterans Health Administration Electronic Health Record System. Pharmacoepidemiology And Drug Safety 2024, 33: e70024. PMID: 39477692, DOI: 10.1002/pds.70024.Peer-Reviewed Original ResearchConceptsVeterans Health Administration dataHealth administrative dataAdministrative dataElectronic health record systemsHealth record systemsInternational Classification of DiseasesCoding algorithmOutpatient International Classification of DiseasesPositive predictive valueClassification of DiseasesHepatic decompensationDiagnosis codesPharmacoepidemiologic researchMedical recordsVeteransRecording systemValidation algorithmAlgorithmChronic liver diseaseDecompensationLiver diseasePredictive valueRecordsDiagnosisThe Association Between Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Exposure and Key Cirrhosis-Related Outcomes.
Wang R, Serper M, Taddei T, Kaplan D, Mahmud N. The Association Between Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Exposure and Key Cirrhosis-Related Outcomes. The American Journal Of Gastroenterology 2024 PMID: 39051649, DOI: 10.14309/ajg.0000000000002976.Peer-Reviewed Original ResearchAssociated with hepatic decompensationAngiotensin-converting enzyme inhibitorsAssociated with reduced mortalityAngiotensin receptor blockersACE-I/ARBConverting enzyme inhibitorsCV-related mortalityHepatocellular carcinomaHepatic decompensationCox regressionAngiotensin receptor blocker exposureEnzyme inhibitorsVeterans Health AdministrationCalcium channel blockersSubsets of patientsChronic liver diseaseCause-specific hazard modelInverse probability treatmentIdentified new initiatorsOutcome of mortalityNew initiativesCirrhosis decompensationCompensated cirrhosisDecompensated cirrhosisChannel blockersAccuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline.
Patel K, Asrani S, Fiel M, Levine D, Leung D, Duarte-Rojo A, Dranoff J, Nayfeh T, Hasan B, Taddei T, Alsawaf Y, Saadi S, Majzoub A, Manolopoulos A, Alzuabi M, Ding J, Sofiyeva N, Murad M, Alsawas M, Rockey D, Sterling R. Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline. Hepatology 2024 PMID: 38489517, DOI: 10.1097/hep.0000000000000842.Peer-Reviewed Original ResearchAminotransferase-to-platelet ratio indexChronic liver diseaseNonalcoholic fatty liver diseaseHepatitis B virusBlood-based biomarkersLiver diseaseFIB-4HIV-HCV co-infectionCo-infectionFIB-4 <Alternative to liver biopsyFIB-4 >Pre-test probabilityBlood-based testLiver disease assessmentSystematic reviewStaging liver fibrosisComprehensive search of databasesHIV-HCVFatty liver diseaseProportional odds ratiosAdvanced fibrosisLiver biopsyViral hepatitisB virus
2023
Adherence to Tumor Board Recommendations in the Treatment of Patients with Hepatocellular Carcinoma
Cao Y, Mezzacappa C, Jaffe A, Strazzabosco M, Taddei T. Adherence to Tumor Board Recommendations in the Treatment of Patients with Hepatocellular Carcinoma. Journal Of Multidisciplinary Healthcare 2023, 16: 1531-1540. PMID: 37283950, PMCID: PMC10239642, DOI: 10.2147/jmdh.s407908.Peer-Reviewed Original ResearchMultidisciplinary liver tumor boardBarcelona Clinic Liver CancerHepatocellular carcinomaBCLC stageLocoregional therapyTreatment-naïve hepatocellular carcinomaTreatment of HCCTumor board recommendationsRetrospective cohort studyTertiary care centerChronic liver diseaseMultivariate Cox regressionKaplan-Meier analysisManagement of patientsTreatment of patientsUnifocal hepatocellular carcinomaCases of discordanceBCLC guidelinesPalliative intentTreatment discordanceUnifocal diseaseChart reviewCohort studyCurative therapyCurative treatmentEnhanced Identification of Hispanic Ethnicity Using Clinical Data
Ochoa-Allemant P, Tate J, Williams E, Gordon K, Marconi V, Bensley K, Rentsch C, Wang K, Taddei T, Justice A, Cohorts F. Enhanced Identification of Hispanic Ethnicity Using Clinical Data. Medical Care 2023, 61: 200-205. PMID: 36893404, PMCID: PMC10114212, DOI: 10.1097/mlr.0000000000001824.Peer-Reviewed Original ResearchConceptsBurden of diseaseHispanic patientsCountry of birthClinical dataHispanic ethnicityNon-Hispanic white patientsSex-adjusted prevalenceChronic liver diseaseHuman immunodeficiency virusDemographic characteristicsElectronic health record dataHealth careHealth record dataPrevalence of conditionsUS health care systemMedicare administrative dataHealth care systemWhite patientsLiver diseaseImmunodeficiency virusSelf-reported ethnicityHigh prevalenceGastric cancerHepatocellular carcinomaVeteran population
2022
Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook
Jaffe A, Taddei TH, Giannini EG, Ilagan‐Ying Y, Colombo M, Strazzabosco M. Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook. Liver International 2022, 42: 2607-2619. PMID: 36161463, PMCID: PMC10878125, DOI: 10.1111/liv.15432.Peer-Reviewed Original ResearchConceptsLiver diseaseHepatocellular carcinomaLiver functionRisk factorsRelevant prognostic roleChronic hepatitis BResidual liver functionChronic liver diseaseManagement of patientsCare of patientsCommon risk factorsAppropriate surveillance strategiesSuccessful cancer treatmentC infectionCommon complicationHepatitis BMetabolic syndromePrognostic roleSignificant morbidityLongitudinal careCurrent careCancer recurrenceHCC managementLiver cancerHCC treatmentAttacking the public health crisis of hepatocellular carcinoma at its roots
Lee HM, Lidofsky SD, Taddei TH, Townshend‐Bulson L. Attacking the public health crisis of hepatocellular carcinoma at its roots. Hepatology 2022, 77: 1456-1459. PMID: 35989555, PMCID: PMC10026951, DOI: 10.1002/hep.32741.Peer-Reviewed Original ResearchConceptsHepatitis B virusLiver diseasePublic health crisisHepatocellular carcinomaChronic hepatitis B virusAlcohol-related liver diseaseNonalcoholic fatty liver diseaseChronic liver diseaseFatty liver diseasePrincipal risk factorsCancer-related deathSignificant mortality ratePrevention of HCCHealth crisisViral hepatitisTreatment advancesB virusRisk factorsCurable stageCommon causeRisk populationsHCC detectionRisk individualsMortality rateSurveillance programCOVID-19 and the liver: a narrative review of the present state of knowledge
Thandassery RB, Dranoff JA, Perisetti A, Taddei T. COVID-19 and the liver: a narrative review of the present state of knowledge. Translational Gastroenterology And Hepatology 2022, 0: 0-0. PMID: 36300154, PMCID: PMC9468988, DOI: 10.21037/tgh-20-243.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsChronic liver diseaseLiver diseaseLiver injuryComorbid conditionsAcute respiratory distress syndromeDirect viral cytotoxicityNon-immunosuppressed patientsAdvanced liver diseaseLiver function testsThird of patientsEpithelial cellsRespiratory distress syndromeResolution of diseaseResolution of illnessOngoing pandemicNovel corona virus diseaseType 2 pneumocytesCOVID-19Biliary epithelial cellsGastrointestinal epithelial cellsCorona Virus DiseaseLiver dysfunctionDistress syndromeFunction testsUninterrupted careStatin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort
Mahmud N, Chapin S, Goldberg DS, Reddy KR, Taddei TH, Kaplan DE. Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort. Journal Of Hepatology 2022, 76: 1100-1108. PMID: 35066085, PMCID: PMC9018495, DOI: 10.1016/j.jhep.2021.12.034.Peer-Reviewed Original ResearchConceptsChronic liver failureStatin exposureLiver failureStatin useCohort studyChronic liver failure developmentInverse probability treatment weightingProportional hazards regression modelsDoses of statinsVeterans Affairs cohortRetrospective cohort studyChronic liver diseaseHazards regression modelsLarge national cohortVeterans Health AdministrationNumerous beneficial effectsMarginal structural modelsMedian followStatin therapyLiver diseaseNational cohortACLFTreatment weightingCirrhosisPatientsOral Cyanobacteria and Hepatocellular Carcinoma
Hernandez BY, Zhu X, Risch HA, Lu L, Ma X, Irwin ML, Lim JK, Taddei TH, Pawlish KS, Stroup AM, Brown R, Wang Z, Wong LL, Yu H. Oral Cyanobacteria and Hepatocellular Carcinoma. Cancer Epidemiology Biomarkers & Prevention 2022, 31: 221-229. PMID: 34697061, PMCID: PMC8755591, DOI: 10.1158/1055-9965.epi-21-0804.Peer-Reviewed Original ResearchConceptsHepatitis B virusHepatitis C virusHepatocellular carcinomaRisk factorsLiver diseaseHCC casesOral microbiomeU.S. case-control studyIndependent risk factorChronic liver diseaseFatty liver diseaseHCC risk factorsGut microbial alterationsType 2 diabetesCase-control studyLiver cancer developmentNSAID useAspirin useC virusB virusHCC riskNegative historyOral samplesSignificant associationCancer development
2021
Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin
Saffo S, Kaplan DE, Mahmud N, Serper M, John BV, Ross JS, Taddei T. Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin. Diabetes Obesity And Metabolism 2021, 23: 2402-2408. PMID: 34227216, PMCID: PMC8429193, DOI: 10.1111/dom.14488.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsDipeptidyl peptidase-4 inhibitorsPeptidase-4 inhibitorsDiabetes mellitusLiver diseaseNon-alcoholic fatty liver diseaseCotransporter 2 inhibitorsChronic liver diseaseFatty liver diseaseVeterans Affairs hospitalIncidence of ascitesAdditional pharmacotherapyTreat analysisElectronic health dataSGLT2 inhibitorsSGLT2i usersSurrogate biomarkerDPP4 inhibitorsMetabolic effectsPatientsCirrhosisPropensity scoreAscitesConfirmatory studiesMetforminSACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation
Kaplan D, Mehta R, Garcia-Tsao G, Albrecht J, Aytaman A, Baffy G, Bajaj J, Hernaez R, Hunt K, Ioannou G, Johnson K, Kanwal F, Lee T, Monto A, Pandya P, Schaubel D, Taddei T. SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation. Contemporary Clinical Trials 2021, 104: 106367. PMID: 33771685, PMCID: PMC8422958, DOI: 10.1016/j.cct.2021.106367.Peer-Reviewed Original ResearchConceptsHepatic decompensationPortal hypertensionEvents of decompensationHepatic decompensation eventsLiver-related deathSignificant portal hypertensionAcceptable safety profileProspective human studiesRole of statinsChronic liver diseaseClasses of medicationsPatient-reported outcomesDevelopment of decompensationEffect of simvastatinVA Medical CenterCompensated cirrhosisDecompensation eventsStatin therapyVariceal hemorrhageCirrhotic patientsStandard therapyVascular reactivityExert pleiotropic effectsLiver diseaseRetrospective study
2019
Risk prediction scores for acute on chronic liver failure development and mortality
Mahmud N, Hubbard RA, Kaplan DE, Taddei TH, Goldberg DS. Risk prediction scores for acute on chronic liver failure development and mortality. Liver International 2019, 40: 1159-1167. PMID: 31840390, PMCID: PMC7371261, DOI: 10.1111/liv.14328.Peer-Reviewed Original ResearchConceptsShort-term mortalityRisk prediction scoreACLF mortalityACLF scoreLiver diseaseChronic Liver Failure Consortium ACLF scoreChronic liver failure developmentCLIF-C ACLF scoreStable chronic liver diseaseVeterans Health Administration databaseEnd-stage liver diseaseHigh short-term mortalityEarly transplant referralChronic liver failureRetrospective cohort studyEscalation of careChronic liver diseaseUnited States cohortMultivariable logistic regressionNovel risk prediction scorePrediction scoreHealth Administration databaseGood discriminationACLF criteriaIncident cirrhosisIncidence and Mortality of Acute‐on‐Chronic Liver Failure Using Two Definitions in Patients with Compensated Cirrhosis
Mahmud N, Kaplan DE, Taddei TH, Goldberg DS. Incidence and Mortality of Acute‐on‐Chronic Liver Failure Using Two Definitions in Patients with Compensated Cirrhosis. Hepatology 2019, 69: 2150-2163. PMID: 30615211, PMCID: PMC6461492, DOI: 10.1002/hep.30494.Peer-Reviewed Original ResearchConceptsHigh short-term mortalityChronic liver failureShort-term mortalityIncidence rateCompensated cirrhosisLiver failureLiver diseaseLiver functionNonalcoholic fatty liver diseaseMedian bilirubin levelRetrospective cohort studyChronic liver diseaseFatty liver diseaseMajority of patientsVeterans Health AdministrationACLF criteriaACLF incidenceAPASL criteriaHepatitis CCohort studyBilirubin levelsPatient groupAcute insultACLFCirrhosis
2017
Healthcare Costs Related to Treatment of Hepatocellular Carcinoma Among Veterans With Cirrhosis in the United States
Kaplan DE, Chapko MK, Mehta R, Dai F, Skanderson M, Aytaman A, Baytarian M, D’Addeo K, Fox R, Hunt K, Pocha C, Valderrama A, Taddei TH, Group V. Healthcare Costs Related to Treatment of Hepatocellular Carcinoma Among Veterans With Cirrhosis in the United States. Clinical Gastroenterology And Hepatology 2017, 16: 106-114.e5. PMID: 28756056, PMCID: PMC5735018, DOI: 10.1016/j.cgh.2017.07.024.Peer-Reviewed Original ResearchConceptsMultivariable generalized linear modelsMultidisciplinary tumor boardHepatocellular carcinomaIntegrated health systemCancer-related costsHealthcare costsLiver transplantationBCLC stageLiver diseaseTumor boardBarcelona Clinic Liver Cancer stageVeterans Affairs Corporate Data WarehouseHealth systemCases of HCCBasis of receiptLiver disease cohortReceipt of transplantationLiver disease etiologyChronic liver diseaseLiver Cancer stageLiver cancer surveillanceBasis of severityHospital academic affiliationCorporate Data WarehouseCirrhosis controls
2012
HCC Is promoted by bacterial translocation and TLR‐4 signaling: A new paradigm for chemoprevention and management
Toffanin S, Cornella H, Harrington A, Llovet J, Groszmann R, Iwakiri Y, Taddei T. HCC Is promoted by bacterial translocation and TLR‐4 signaling: A new paradigm for chemoprevention and management. Hepatology 2012, 56: 1998-2000. PMID: 23115011, DOI: 10.1002/hep.26080.Peer-Reviewed Original ResearchHepatocellular carcinomaToll-like receptorsIntestinal microbiotaLiver diseaseTranslocation of intestinal bacteriaResident liver cellsAdvanced liver diseaseChronically injured liverHepatocellular carcinoma preventionConsequence of chronic liver injuryTLR-4 signalingChronic liver diseaseChronic liver injuryHepatocellular carcinoma initiationHCC promotionPrevention of apoptosisBacterial translocationTLR-4Liver injuryHepatic inflammationTLR4 activationIncreased proliferationLong-term consequencesTherapeutic targetTLR4Exploring beyond cirrhosis
Pinzani M, Groszmann R, Iwakiri Y, Taddei T. Exploring beyond cirrhosis. Hepatology 2012, 56: 778-780. PMID: 22833249, DOI: 10.1002/hep.25775.Peer-Reviewed Original ResearchChronic liver diseaseLiver diseaseComplications of portal hypertensionNatural history of cirrhosisHistory of cirrhosisStage of chronic liver diseaseTreatment of chronic liver diseaseAdvanced stage of chronic liver diseaseGrade of activityAdverse prognosisPortal hypertensionLiver failureHepatocellular carcinomaClinicopathological assessmentStudy groupCirrhosisRisk factorsNatural historyDiseaseEnd stage